Back

Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pharmacotherapy 5 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Miss Martina Amiguet Comins

General University Hospital of Castellon, Castellon de la Plana (Spain)

5 More presentations in this session

Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series
Doctor J. Brito (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Trace element equilibrium in acute heart failure and the effect of empagliflozin
Assistant Professor N. Bomer (Groningen, NL)
Abstract Slides
Presentation thumbnail
Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides
Presentation thumbnail
Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction
Doctor J. Youn (Seoul, KR)
Abstract Slides
Presentation thumbnail
REALM-DCM: a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 (PF-07265803) in patients with symptomatic LMNA-related dilated cardiomyopathy
Doctor R. Barriales-Villa (Coruna, A, ES)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - pharmacotherapy 5

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources